Tegoprazan is a potassium-competitive blocker of hydrochloric acid secretion

Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new class of drugs that can completely block the potassium-binding site of the gastric H+/K+ ATPase, potentially overcoming the limitations of proton pump inhibitors (PPIs). Tegoprazan was developed by CJ Healthcare (Republic of Korea) for the treatment of gastroesophageal reflux disease and Helicobacter pylori infection. Tegoprazan is independent of CYP2C19 metabolism, which emphasizes its importance in decision-making on difficult-to-treat conditions such as peptic ulcer, refractory gastroesophageal reflux, antibiotic-resistant H. Pylori, especially in some regions of the geographic regions. High efficiency of tegoprazan in the treatment of nocturnal acid breakthroughs, when used in 14-day eradication regimens together with bismuth, clarithromycin, recommended by international and national professional societies. When comparing the efficacy and safety with various PPIs and other P-CABs used to treat acid-related diseases, tegoprazan shows a small number of easily tolerated and eliminated undesirable side effects. Tegoprazan demonstrates a rapid onset of action, direct action on the proton pump (without turning into a prodrug), its complete inhibition starting from the starting dose, a high duration of the therapeutic effect, prevention of nocturnal acid breakthrough, can be taken regardless of meal time.